Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | CPS1 | P31327 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23386065 | 0.86 | POLB (0.65) | POLBMTNR1AESR1CYP19A1ESR2 | |
| SCHEMBL2723938 | 0.81 | POLB (0.77) | POLBFFAR4FFAR1 | |
| SCHEMBL16898440 | 0.80 | MAOB (0.44) | FFAR4FFAR1 | |
| SCHEMBL1924061 | 0.79 | POLB (0.56) | POLBFFAR1 | |
| SCHEMBL5024499 | 0.78 | ESR1 (0.49) | POLBESR1CYP19A1ESR2 | |
| SCHEMBL20244569 | 0.78 | POLB (0.55) | POLBFFAR4MTNR1BCPS1FFAR1 | |
| SCHEMBL14430371 | 0.77 | POLB (0.61) | POLBMTNR1AFFAR4MTNR1BFFAR1 | |
| SCHEMBL3316261 | 0.77 | MTNR1A (0.61) | POLBMTNR1AMTNR1BFFAR1 | |
| SCHEMBL5121065 | 0.77 | ALOX5 (0.66) | POLB | |
| SCHEMBL11224282 | 0.77 | ESR1 (0.47) | ESR1CYP19A1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3608306-B1 | CRYSTAL FORM AND AMORPHOUS FORM OF DEZOCINE ANALOGUE HYDROCHLORIDE | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2022-05-25 | — | — | EP | disclosed |
| US-11339119-B2 | Crystal form and amorphous form of dezocine analogue hydrochloride | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2022-05-24 | — | — | US | disclosed |
| US-20210147341-A1 | CRYSTAL FORM AND AMORPHOUS FORM OF DEZOCINE ANALOGUE HYDROCHLORIDE | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2021-05-20 | — | — | US | disclosed |
| EP-3608306-A1 | CRYSTAL FORM AND AMORPHOUS FORM OF DEZOCINE ANALOGUE HYDROCHLORIDE | Shandong Danhong Pharmaceutical Co., Ltd. (CN) | 2020-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147341-A1 | CRYSTAL FORM AND AMORPHOUS FORM OF DEZOCINE ANALOGUE HYDROCHLORIDE | DAZAP1, IDUA, SIGMAR1 | POLB 4608/4885MTNR1A 688/4885ESR1 4855/4885 |
| US-11339119-B2 | Crystal form and amorphous form of dezocine analogue hydrochloride | DAZAP1, IDUA, SIGMAR1 | POLB 4608/4885MTNR1A 688/4885ESR1 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.